Showing results (1-10 of 127) with videos related to
Sort By:
Pageof 13
Clinical Neurology and Neurosurgery|December 11, 2013
Teriflunomide for the treatment of multiple sclerosisClemens Warnke, Olaf Stüve, Bernd C KieseierTrends in Pharmacological Sciences|October 27, 2015
PML: The Dark Side of Immunotherapy in Multiple SclerosisClemens Warnke, Tomas Olsson, Hans-Peter HartungJournal of Neural Transmission (Vienna, Austria : 1996)|June 25, 2013
Biotherapeutics for the treatment of multiple sclerosis: hopes and hazardsClemens Warnke, Bernd C Kieseier, Hans-Peter HartungEurope'S Journal of Psychology|January 6, 2023
A Network Perspective on Neuropsychiatric and Cognitive Symptoms of the Post-COVID SyndromeDaniel Scharfenberg, Ann-Katrin Schild, Clemens Warnke, et al.Journal of Neurology|May 10, 2020
Application of "Mentzer's PML case definition" to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilanceMartijn T Wijburg, Clemens Warnke, Joep Killestein, et al.Journal of the Peripheral Nervous System : JPNS|March 13, 2016
Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous systemVerena-Isabell Leussink, Mark Stettner, Clemens Warnke, et al.Expert Review of Neurotherapeutics|August 24, 2016
Ocrelizumab for the treatment of relapsing-remitting multiple sclerosisTil Menge, Divyanshu Dubey, Clemens Warnke, et al.Brain and Behavior|July 22, 2021
Type O blood group associates with higher anti-JC polyomavirus antibody levelsPia Frenken, Hans-Peter Hartung, Tomas Olsson, et al.Fortschritte Der Neurologie-Psychiatrie|February 11, 2021
[Dysphagia in Multiple Sclerosis - an underestimated symptom?]Carolin Eckardt, Sabine Ulrike Vay, Clemens Warnke, et al.Drug Design, Development and Therapy|August 7, 2010
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineClemens Warnke, Heinz Wiendl, Hans-Peter Hartung, et al.Pageof 13